Final OS results of the POLO trial in
#PancreaticCancer
out in
@ASCO
@JCO_ASCO
mOS: 19.0 vs 19.2 months ➡️no difference but
Median time to 1st & 2nd subsequent
#cancer
tx
& time to discontinuation of study tx favoured olaparib.
@OncoAlert
🚨
#pancsm
💜
10
16
58
Replies
@BenWestphalen
@JCO_ASCO
@ASCO
@OncoAlert
When one stops treatment to the control arm participants having metastatic pancreatic cancer after only 4cycles of chemo ….then such conclusions seem forced
2
0
1
@drsayandas
@JCO_ASCO
@ASCO
@OncoAlert
Can you elaborate?
Inclusion was at least 16 weeks stable under platinum based CTX - that would be eight cycles of FOLFIRINOX (most patients) or 5-6 cycles of Gem/Cis.
Or am I misunderstanding you?
1
0
0
@BenWestphalen
@JCO_ASCO
@ASCO
@OncoAlert
Thanks for the update! Unfortunately, it doesn’t add benefit, especially having in mind Study Entry criteria..
Not sure, what else can we do to identify potential Olaparib benefit
1
0
0
@VladaIORS
@JCO_ASCO
@ASCO
@OncoAlert
Well…I believe you can use it to achieve chemotherapy free time for your patients.
Key is to realize when to re-induce chemo after “holiday”.
Also question is, when to start maintenance - wait for deepest response and then switch vs earlier.
1
0
1
@BenWestphalen
@JCO_ASCO
@ASCO
@OncoAlert
PFS may be chosen as a surrogate for rapid approval of new treatments due to concerns that OS will take a long time to conclude. However, I do not understand why OS was not chosen as the primary endpoint when the median OS in metastatic pancreatic cancer is around one year.
0
0
12
@BenWestphalen
@ASCO
@JCO_ASCO
@OncoAlert
Time to next treatment was longer?
To achieve this they had to stay on treatment as opposed to the control group getting placebo. The second the olaparib pill was swallow is the time to next treatment which equals 0 minutes.
0
3
27
@BenWestphalen
@ASCO
@JCO_ASCO
@OncoAlert
The drug has failed. It is as simple as that. Rest all is postive " SPIN OFF " by medical writers. I really appreciate that efforts . Must be a real tough job .
0
0
2
@BenWestphalen
@ASCO
@JCO_ASCO
@OncoAlert
And Don't miss that OS is actually more in Placebo arm . Numerically 😃😃
0
0
1
@BenWestphalen
@ASCO
@JCO_ASCO
@OncoAlert
Very disappointed in the study results. Wish we had something to show in terms of survival benefit in pancreatic cancer.
0
0
0
@BenWestphalen
@ASCO
@JCO_ASCO
@OncoAlert
No OS difference striking particularly given that control arm essentially had a treatment holiday. Frustrating study design.
1
0
2
@BenWestphalen
@ASCO
@JCO_ASCO
@OncoAlert
Disappointed that this didn’t demonstrate anything worthwhile however it least a negative study was published and is getting exposure! That’s important too!
0
0
0
0
0
1